A Study of TRK-170 for the Treatment of Crohn's Disease
A Two Part, Multi-Centre, Randomized, Placebo-Controlled, Double-Blind Study of TRK-170 for the Treatment of Crohn's Disease
In Crohn's Disease Patients
- To evaluate the efficacy of TRK-170
- To evaluate the PK characteristics of TRK-170
- To assess the safety of TRK-170
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Belgium, Belgium
- Belgium
-
-
-
-
-
Bulgaria, Bulgaria
- Bulgaria
-
-
-
-
-
Czech Republic, Czech Republic
- Czech Republic
-
-
-
-
-
France, France
- France
-
-
-
-
-
Hungary, Hungary
- Hungary
-
-
-
-
-
Latvia, Latvia
- Latvia
-
-
-
-
-
The Netherlands, Netherlands
- The Netherlands
-
-
-
-
-
Norway, Norway
- Norway
-
-
-
-
-
Poland, Poland
- Poland
-
-
-
-
-
Romania, Romania
- Romania
-
-
-
-
-
Serbica, Serbia
- Serbia
-
-
-
-
-
Sweden, Sweden
- Sweden
-
-
-
-
-
Ukraine, Ukraine
- Ukraine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient has a diagnosis of Crohn's Disease before screening
- Patient has stable disease activity
Exclusion Criteria:
- Patient has had a clinically significant illness prior to screening
- Patient with clinically significant deviations in laboratory values
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
|
|
Experimental: TRK-170 Low Dose
|
|
|
Experimental: TRK-170 Middle Dose
|
|
|
Experimental: TRK-170 High Dose
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Crohn's Disease Activity Index
Time Frame: 12 weeks
|
8 weeks (treatment), 4 weeks (follow-up)
|
12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 170CDT01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.